{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T00:31:10Z","timestamp":1760142670352,"version":"build-2065373602"},"reference-count":55,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2021,5,1]],"date-time":"2021-05-01T00:00:00Z","timestamp":1619827200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,5,1]],"date-time":"2021-05-01T00:00:00Z","timestamp":1619827200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2021,1,19]],"date-time":"2021-01-19T00:00:00Z","timestamp":1611014400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","em-consulte.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Biomedicine &amp; Pharmacotherapy"],"published-print":{"date-parts":[[2021,5]]},"DOI":"10.1016\/j.biopha.2021.111304","type":"journal-article","created":{"date-parts":[[2021,2,5]],"date-time":"2021-02-05T06:58:51Z","timestamp":1612508331000},"page":"111304","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["Midazolam and hydroxymidazolam plasma concentrations can be monitored with selected biochemical and physiological parameters of palliative care patients"],"prefix":"10.1016","volume":"137","author":[{"given":"Iwona","family":"Zaporowska-Stachowiak","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tomasz","family":"Grabowski","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Katarzyna","family":"Stachowiak-Szymczak","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Karolina","family":"Go\u015bciniak","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Artur","family":"Te\u017cyk","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0643-9706","authenticated-orcid":false,"given":"Maciej","family":"Sopata","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"5","key":"10.1016\/j.biopha.2021.111304_bib0005","doi-asserted-by":"crossref","first-page":"767","DOI":"10.1007\/s11096-015-0094-3","article-title":"Medication use during end-of-life care in a palliative care centre","volume":"37","author":"Masman","year":"2015","journal-title":"Int. J. Clin. Pharm."},{"key":"10.1016\/j.biopha.2021.111304_bib0010","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1001\/archinte.163.3.341","article-title":"Sedative use in the last week of life and the implications for end-of-life decision making","volume":"163","author":"Sykes","year":"2003","journal-title":"Arch. Intern. Med."},{"issue":"4","key":"10.1016\/j.biopha.2021.111304_bib0015","doi-asserted-by":"crossref","first-page":"282","DOI":"10.1016\/S0885-3924(01)00258-5","article-title":"Effects of high dose opioids and sedatives on survival in terminally ill cancer patients","volume":"21","author":"Morita","year":"2001","journal-title":"J. Pain Symptom Manage."},{"key":"10.1016\/j.biopha.2021.111304_bib0020","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1016\/0885-3924(90)90020-K","article-title":"Subcutaneous midazolam infusion in palliative care","volume":"5","author":"Bottomley","year":"1990","journal-title":"J. Pain Symptom Manage."},{"key":"10.1016\/j.biopha.2021.111304_bib0025","unstructured":"IAHPC List of Essential Medicines for Palliative Care [online] International Association for Hospice and Palliative Care, Houston (TX): [July 30, 2012]. [Updated 2011 Sept 17]. Available on: http:\/\/www.hospicecare.com\/resources\/pdf-docs\/iahpc-essential-meds-en.pdf."},{"issue":"6","key":"10.1016\/j.biopha.2021.111304_bib0030","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1016\/S0885-3924(98)00020-7","article-title":"Indications and limitations of intravenous and subcutaneous midazolam in a palliative care center","volume":"15","author":"Gremaud","year":"1998","journal-title":"J. Pain Symptom Manage."},{"issue":"1","key":"10.1016\/j.biopha.2021.111304_bib0035","first-page":"5","article-title":"Treatment of terminal restlessness: a review of the evidence","volume":"18","author":"Kehl","year":"2004","journal-title":"J. Pain Palliat. Care Pharmacother."},{"issue":"5","key":"10.1016\/j.biopha.2021.111304_bib0040","doi-asserted-by":"crossref","first-page":"820","DOI":"10.1016\/j.jpainsymman.2009.10.003","article-title":"Morphine versus midazolam as upfront therapy to control dyspnea perception in cancer patients while its underlying cause is sought or treated","volume":"39","author":"Navigante","year":"2010","journal-title":"J. Pain Symptom Manage."},{"issue":"3","key":"10.1016\/j.biopha.2021.111304_bib0045","doi-asserted-by":"crossref","first-page":"478","DOI":"10.1111\/j.1528-1167.2009.02333.x","article-title":"A comparison of midazolam nasal spray and diazepam rectal solution for the residential treatment of seizure exacerbations","volume":"51","author":"de Haan","year":"2011","journal-title":"Epilepsia"},{"issue":"2","key":"10.1016\/j.biopha.2021.111304_bib0050","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1097\/WCO.0b013e3283446f31","article-title":"The treatment of status epilepticus","volume":"24","author":"Shorvan","year":"2011","journal-title":"Curr. Opin. Neurol."},{"issue":"2","key":"10.1016\/j.biopha.2021.111304_bib0055","doi-asserted-by":"crossref","first-page":"89","DOI":"10.4103\/2279-042X.155758","article-title":"Midazolam premedication for Ketamine-induced emergence phenomenon: a prospective observational study","volume":"4","author":"Perumal","year":"2015","journal-title":"J. Res. Pharm. Pract."},{"year":"2012","series-title":"Drugs in Palliative Care","author":"Dickman","key":"10.1016\/j.biopha.2021.111304_bib0060"},{"key":"10.1016\/j.biopha.2021.111304_bib0065","article-title":"Adding midazolam to ketamine for procedural sedation reduces emergence reactions in adults","author":"Richard","year":"2011","journal-title":"NEJM J. Watch"},{"issue":"1","key":"10.1016\/j.biopha.2021.111304_bib0070","first-page":"62","article-title":"The use of midazolam and haloperidol in cancer patients at the end of life","volume":"53","author":"Radha Krishna","year":"2012","journal-title":"Singapore Med. J."},{"issue":"1","key":"10.1016\/j.biopha.2021.111304_bib0075","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1089\/jpm.2012.0205","article-title":"OPCARE9. Four essential drugs needed for quality care of the dying: a Delphi-study based international expert consensus opinion","volume":"16","author":"Lindqvist","year":"2013","journal-title":"J. Palliat. Med."},{"issue":"1","key":"10.1016\/j.biopha.2021.111304_bib0080","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1089\/jpm.2006.0139","article-title":"Palliative sedation therapy in the last weeks of life: a literature review and recommendations for standards","volume":"10","author":"de Graeff","year":"2007","journal-title":"J. Palliat. Med."},{"issue":"5","key":"10.1016\/j.biopha.2021.111304_bib0085","doi-asserted-by":"crossref","first-page":"771","DOI":"10.1016\/j.jpainsymman.2008.04.020","article-title":"Controlled sedation for refractory symptoms in dying patients","volume":"37","author":"Mercadante","year":"2009","journal-title":"J. Pain Symptom Manage."},{"year":"2017","series-title":"Basic and Clinical Pharmacology 14e","author":"Katzung","key":"10.1016\/j.biopha.2021.111304_bib0090"},{"issue":"3","key":"10.1016\/j.biopha.2021.111304_bib0095","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1016\/S0736-4679(97)00022-X","article-title":"Midazolam \u2013 a review of therapeutic uses and toxicity","volume":"15","author":"Nordt","year":"1997","journal-title":"J. Emerg. Med."},{"issue":"6","key":"10.1016\/j.biopha.2021.111304_bib0100","first-page":"403","article-title":"Sedative and cardiovascular effects of midazolam and diazepam alone or combined with clonidine in patients undergoing hemodynamic studies for suspected coronary artery disease","volume":"89","author":"Nascimento","year":"2007","journal-title":"Arq. Bras. Cardiol."},{"issue":"1","key":"10.1016\/j.biopha.2021.111304_bib0105","doi-asserted-by":"crossref","first-page":"R32","DOI":"10.1186\/cc3010","article-title":"Differentiating midazolam over-sedation from neurological damage in the intensive care unit","volume":"9","author":"McKenzie","year":"2005","journal-title":"Crit. Care"},{"key":"10.1016\/j.biopha.2021.111304_bib0110","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1111\/j.1365-2044.1996.tb07785.x","article-title":"What changes drug metabolism in critically ill patients-III? Effect of pre-existing disease on the metabolism of midazolam","volume":"51","author":"Park","year":"1996","journal-title":"Anaesthesia"},{"key":"10.1016\/j.biopha.2021.111304_bib0115","first-page":"149","article-title":"The effects of acute changes in renal function on the pharmacokinetics of midazolam during long-term infusion in ICU patients","volume":"42","author":"Driessen","year":"2019","journal-title":"Acta Anaesthesiol. Belg."},{"issue":"1","key":"10.1016\/j.biopha.2021.111304_bib0120","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1159\/000180580","article-title":"Prediction of creatinine clearance from serum creatinine","volume":"16","author":"Cockcroft","year":"1976","journal-title":"Nephron"},{"issue":"5","key":"10.1016\/j.biopha.2021.111304_bib0125","doi-asserted-by":"crossref","first-page":"566","DOI":"10.1016\/0197-2456(91)90069-X","article-title":"Design and statistical issues of the Modification of Diet in Renal Disease Trial. The Modification of Diet in Renal Disease Study Group","volume":"12","author":"Beck","year":"1991","journal-title":"Control. Clin. Trials"},{"key":"10.1016\/j.biopha.2021.111304_bib0130","doi-asserted-by":"crossref","first-page":"1908","DOI":"10.1038\/ki.1997.260","article-title":"Predictors of the progression of renal disease in the modification of diet in renal disease study","volume":"51","author":"Hunsicker","year":"1997","journal-title":"Kidney Int."},{"issue":"6","key":"10.1016\/j.biopha.2021.111304_bib0135","doi-asserted-by":"crossref","first-page":"461","DOI":"10.7326\/0003-4819-130-6-199903160-00002","article-title":"A more accurate method to estimate glomerular filtration rate from serum creatinine: a new prediction equation. Modification of Diet in Renal Disease Study Group","volume":"130","author":"Levey","year":"1999","journal-title":"Ann. Intern. Med."},{"key":"10.1016\/j.biopha.2021.111304_bib0140","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1002\/jcsm.12053","article-title":"Association of estimated glomerular filtration rate with all -cause and cardiovascular mortality: the role of malnutrition-inflammation- cachexia syndrome","volume":"7","author":"Ou","year":"2016","journal-title":"J. Cachexia Sarcopenia Muscle"},{"issue":"9","key":"10.1016\/j.biopha.2021.111304_bib0145","doi-asserted-by":"crossref","first-page":"604","DOI":"10.7326\/0003-4819-150-9-200905050-00006","article-title":"CKD-EPI (Chronic Kidney Disease Epidemiology Collaboration). A new equation to estimate glomerular filtration rate","volume":"150","author":"Levey","year":"2011","journal-title":"Ann. Intern. Med."},{"key":"10.1016\/j.biopha.2021.111304_bib0150","doi-asserted-by":"crossref","first-page":"630","DOI":"10.1016\/S0009-9236(99)90084-X","article-title":"The effect of age on the pharmacokinetics and pharmacodynamics of midazolam","volume":"65","author":"Albrecht","year":"1999","journal-title":"Clin. Pharmacol. Ther."},{"volume":"1st volume","year":"1993","author":"Kubinyi","key":"10.1016\/j.biopha.2021.111304_bib0155"},{"key":"10.1016\/j.biopha.2021.111304_bib0160","doi-asserted-by":"crossref","first-page":"1660","DOI":"10.3390\/molecules14051660","article-title":"On two novel parameters for validation of predictive QSAR models","volume":"14","author":"Pratim","year":"2009","journal-title":"Molecules"},{"issue":"3","key":"10.1016\/j.biopha.2021.111304_bib0165","doi-asserted-by":"crossref","first-page":"953","DOI":"10.1016\/j.tiv.2010.01.003","article-title":"Correlations between no observed effect level and selected parameters of the chemical structure for veterinary drugs","volume":"24","author":"Grabowski","year":"2010","journal-title":"Toxicol. In Vitro"},{"year":"2003","series-title":"Nature-inspired Methods in Chemometrics: Genetic Algorithms and Artificial Neural Networks: Genetic Algorithms and Artificial Neural Networks","author":"Leardi","key":"10.1016\/j.biopha.2021.111304_bib0170"},{"key":"10.1016\/j.biopha.2021.111304_bib0175","series-title":"The Report From the Expert Group on (Quantitative) Structure-Activity Relationships [(Q)SARs] on the Principles for the Validation of (Q)SARs","first-page":"11","author":"OECD","year":"2004"},{"key":"10.1016\/j.biopha.2021.111304_bib0180","series-title":"OECD, Series on Testing and Assessment","first-page":"1","article-title":"Guidance document on the validation of (quantitative) structure-activity relationships [(Q)SAR] models","author":"OECD","year":"2007"},{"issue":"2 Suppl. 1","key":"10.1016\/j.biopha.2021.111304_bib0185","first-page":"S1","article-title":"[K\/DOQI] Clinical practice guidelines for chronic kidney disease: evaluation, classification, and stratification. National Kidney Foundation","volume":"39","year":"2002","journal-title":"Am. J. Kidney Dis."},{"issue":"5","key":"10.1016\/j.biopha.2021.111304_bib0190","doi-asserted-by":"crossref","first-page":"899","DOI":"10.2215\/CJN.05371008","article-title":"Estimating glomerular filtration rate: Cockcroft-Gault and modification of diet in renal disease formulas compared to renal inulin clearance","volume":"4","author":"Botev","year":"2009","journal-title":"Clin. J. Am. Soc. Nephrol."},{"issue":"4","key":"10.1016\/j.biopha.2021.111304_bib0195","doi-asserted-by":"crossref","first-page":"547","DOI":"10.1159\/000065012","article-title":"Formula-derived prediction of the glomerular filtration rate from plasma creatinine concentration","volume":"91","author":"Kemperman","year":"2002","journal-title":"Nephron"},{"key":"10.1016\/j.biopha.2021.111304_bib0200","doi-asserted-by":"crossref","first-page":"675","DOI":"10.1097\/00041552-199811000-00009","article-title":"Application of newer clearance techniques for the determination of glomerular filtration rate","volume":"7","author":"Gaspari","year":"1998","journal-title":"Curr. Opin. Nephrol. Hypertens."},{"issue":"5","key":"10.1016\/j.biopha.2021.111304_bib0205","doi-asserted-by":"crossref","first-page":"830","DOI":"10.1038\/ki.1985.205","article-title":"Limitations of creatinine as a filtration marker in glomerulopathic patients","volume":"28","author":"Shemesh","year":"1985","journal-title":"Kidney Int."},{"issue":"1","key":"10.1016\/j.biopha.2021.111304_bib0210","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1038\/ki.1985.3","article-title":"125I iothalamate an ideal marker for glomerular filtration?","volume":"27","author":"Odlind","year":"1985","journal-title":"Kidney Int."},{"issue":"3","key":"10.1016\/j.biopha.2021.111304_bib0215","doi-asserted-by":"crossref","first-page":"224","DOI":"10.1016\/S0272-6386(12)81022-5","article-title":"Utility of radioisotopic filtration markers in chronic renal insufficiency: simultaneous comparison of 125I-iothalamate, 169Yb-DTPA, 99mTc-DTPA, and inulin. The modification of diet in renal disease study","volume":"16","author":"Perrone","year":"1990","journal-title":"Am. J. Kidney Dis."},{"issue":"6","key":"10.1016\/j.biopha.2021.111304_bib0220","doi-asserted-by":"crossref","first-page":"832","DOI":"10.1038\/ki.1988.257","article-title":"Serial assessment of glomerular filtration rate in lupus nephropathy","volume":"34","author":"Petri","year":"1988","journal-title":"Kidney Int."},{"issue":"5","key":"10.1016\/j.biopha.2021.111304_bib0225","doi-asserted-by":"crossref","first-page":"1563","DOI":"10.2215\/CJN.00960208","article-title":"Screening for CKD with eGFR: doubts and dangers","volume":"3","author":"Glassock","year":"2008","journal-title":"Clin. J. Am. Soc. Nephrol."},{"key":"10.1016\/j.biopha.2021.111304_bib0230","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1038\/ki.1990.182","article-title":"Measurement of renal function in chronic renal disease","volume":"38","author":"Levey","year":"1990","journal-title":"Kidney Int."},{"issue":"1","key":"10.1016\/j.biopha.2021.111304_bib0235","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1053\/j.ajkd.2012.06.016","article-title":"Accuracy of the MDRD (Modification of Diet in Renal Disease) study and CKD-EPI (CKD Epidemiology Collaboration) equations for estimation of GFR in the elderly","volume":"61","author":"Kilbride","year":"2013","journal-title":"Am. J. Kidney Dis."},{"issue":"2","key":"10.1016\/j.biopha.2021.111304_bib0240","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1159\/000448722","article-title":"SPRINT Research Group. Chronic kidney disease classification in systolic blood pressure intervention trial: comparison using modification of diet in renal disease and CKD-epidemiology collaboration definitions","volume":"44","author":"Rocco","year":"2016","journal-title":"Am. J. Nephrol."},{"issue":"June (6)","key":"10.1016\/j.biopha.2021.111304_bib0245","doi-asserted-by":"crossref","first-page":"1007","DOI":"10.1053\/j.ajkd.2014.01.436","article-title":"Performance of creatinine-based GFR estimating equations in solid-organ transplant recipients","volume":"63","author":"Shaffi","year":"2014","journal-title":"Am. J. Kidney Dis."},{"issue":"2","key":"10.1016\/j.biopha.2021.111304_bib0250","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1053\/j.ajkd.2005.05.011","article-title":"Estimation of renal function in subjects with normal serum creatinine levels: influence of age and body mass index","volume":"46","author":"Verhave","year":"2005","journal-title":"Am. J. Kidney Dis."},{"issue":"11","key":"10.1016\/j.biopha.2021.111304_bib0255","doi-asserted-by":"crossref","first-page":"1979","DOI":"10.1007\/s11255-017-1682-z","article-title":"Estimating renal function in old people: an in-depth review","volume":"49","author":"Maharajan","year":"2017","journal-title":"Int. Urol. Nephrol."},{"issue":"4","key":"10.1016\/j.biopha.2021.111304_bib0260","doi-asserted-by":"crossref","first-page":"1425","DOI":"10.1046\/j.1523-1755.2003.00208.x","article-title":"Predicting GFR in children and adults: a comparison of the Cockcroft-Gault, Schwartz, and modification of diet in renal disease formulas","volume":"64","author":"Pierrat","year":"2003","journal-title":"Kidney Int."},{"key":"10.1016\/j.biopha.2021.111304_bib0265","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1016\/j.jpainsymman.2006.10.015","article-title":"Symptom prevalence in patients with incurable Cancer: a systematic review","volume":"34","author":"Teunissen","year":"2007","journal-title":"J. Pain Symptom Manage."},{"key":"10.1016\/j.biopha.2021.111304_bib0270","first-page":"114","article-title":"Midazolam: safety of use in palliative care: a systematic critical review","author":"Zaporowska-Stachowiak","year":"2019","journal-title":"Biomed. Pharmacother."},{"issue":"2","key":"10.1016\/j.biopha.2021.111304_bib0275","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1016\/j.phrs.2006.11.001","article-title":"Gender differences in drug responses","volume":"55","author":"Franconi","year":"2007","journal-title":"Pharmacol. Res."}],"container-title":["Biomedicine &amp; Pharmacotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0753332221000895?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0753332221000895?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T12:21:54Z","timestamp":1760098914000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0753332221000895"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,5]]},"references-count":55,"alternative-id":["S0753332221000895"],"URL":"https:\/\/doi.org\/10.1016\/j.biopha.2021.111304","relation":{},"ISSN":["0753-3322"],"issn-type":[{"type":"print","value":"0753-3322"}],"subject":[],"published":{"date-parts":[[2021,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Midazolam and hydroxymidazolam plasma concentrations can be monitored with selected biochemical and physiological parameters of palliative care patients","name":"articletitle","label":"Article Title"},{"value":"Biomedicine & Pharmacotherapy","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.biopha.2021.111304","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 The Author(s). Published by Elsevier Masson SAS.","name":"copyright","label":"Copyright"}],"article-number":"111304"}}